Related Experiment Video
Updated: Aug 9, 2026
09:05
Measurement of Smooth Muscle Function in the Isolated Tissue Bath-applications to Pharmacology Research
Published on: January 19, 2015
The properties of beta-adrenoceptor antagonists
Postgraduate Medical Journal
|January 1, 1976
Summary
Beta-blockers effectively treat angina and arrhythmias by blocking beta-adrenoceptors. Additional properties like intrinsic sympathomimetic activity and membrane stabilization do not enhance therapeutic effects in patients.
Area of Science:
- Pharmacology
- Cardiology
Background:
- Clinical studies with pronethalol and propranolol validated the efficacy of beta-adrenoceptor blockers for angina pectoris and cardiac arrhythmias.
- Subsequent research identified additional properties of beta-adrenoceptor blocking drugs, including intrinsic sympathomimetic activity, membrane stabilizing activity, and cardioselectivity.
Purpose of the Study:
- To investigate the pharmacological properties of beta-adrenoceptor blocking drugs beyond their primary blocking action.
- To determine the contribution of intrinsic sympathomimetic activity, membrane stabilizing activity, and cardioselectivity to the therapeutic effectiveness of these drugs in patients.
Main Methods:
- Detailed pharmacological studies of propranolol.
- Comparative analysis of propranolol's properties with other beta-adrenoceptor blocking agents.
- Evaluation of drug effects in laboratory animals, normal humans, and patients.
Main Results:
- Beta-adrenoceptor blocking activity is the primary driver of therapeutic effectiveness in patients.
- Intrinsic sympathomimetic activity and membrane stabilizing activity were not found to contribute significantly to therapeutic outcomes in patients.
- Cardioselectivity may offer benefits for specific patient populations.
Conclusions:
- The therapeutic benefits of beta-adrenoceptor blocking drugs in angina and arrhythmias are primarily attributed to their beta-adrenoceptor blockade.
- Intrinsic sympathomimetic activity and membrane stabilizing activity appear to be less relevant in the clinical application of these drugs.
- Cardioselectivity represents a potentially valuable characteristic for certain patient groups requiring beta-adrenoceptor blockade.
Related Concept Videos
01:17Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:28Antihypertensive Drugs: Types of β-Blockers
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...